Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganagliflozin Proline in Type 2 Diabetes Mellitus with Hyperuricemia and Different eGFR Levels
ChiCTR2500113752Phase 4Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ganagliflozin in type 2 diabetes mellitus (T2DM) and hyperuricemia (3 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: Serum uric acid at week 24. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
ganagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hyperuricemia
Beyond the preview
Go deeper on ChiCTR2500113752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113752.